SCM
CRVS icon

Sterling Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Sterling Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Sell
238
-180
-43% -$2.5K ﹤0.01% 2788
2026
Q1 		$6.12K Buy
418
+26
+7% +$415 ﹤0.01% 2636
2025
Q4 		$3.02K Buy
392
+248
+172% +$1.96K ﹤0.01% 3005
2025
Q3 		$1.06K Buy
144
+17
+13% +$87 ﹤0.01% 3074
2025
Q2 		$508 Buy
+127
New +$462 ﹤0.01% 3151

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sterling Capital Management's CRVS Position: Q2 2026 in Review

Sterling Capital Management reduced its Corvus Pharmaceuticals (CRVS) stake by 43% in Q2 2026, selling an estimated $2.5K and leaving 238 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

Sterling Capital Management first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.12K in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Sterling Capital Management held 238 shares of Corvus Pharmaceuticals worth $3.56K as of Q2 2026.
  • Sterling Capital Management sold 180 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.5K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2788 holding.
  • Sterling Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Corvus Pharmaceuticals position peaked at $6.12K in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.